ATTAIN-1 Trial Highlights: - Mean weight loss of ~12.4% over 72 weeks for patients on the highest dose - Participants lost an average of 25 pounds (11.1%) regardless of trial completion - Safety profile consistent with GLP-1 class
For now, injectable options like semaglutide, prescribed when medically appropriate by a licensed provider, remain the gold standard in GLP-1 treatment
Thats why the FDAs own technical staff has recommended against expanded access, and the public health group Partnership for Safe Medicines calls them "popular, unproven, dangerous. As Peter Kolchinsky, managing partner of biotech investor RA Capital Management, puts it: Is the FDA going to stand on science or is it going to permit all kinds of snake oil to be readily available? The FDA meeting will last two days
Nilsson K, Giovanella BC, Stehlin JS, Klein G
First, BPC-157 vials are commonly supplied at 5 mg per vial and reconstituted to 1 mg/ml using 5 ml of bacteriostatic water the volume matches semaglutide, but the dose math does not